Medinol Ltd.
16
1
2
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
6.3%
1 terminated/withdrawn out of 16 trials
91.7%
+5.2% vs industry average
6%
1 trials in Phase 3/4
45%
5 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
First In Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients With Superficial Femoral Artery Disease and/or Proximal Popliteal Artery Disease
Role: lead
IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System
Role: lead
BIONICS Small Vessels Trial EluNIR Ridaforolimus Eluting Coronary Stent System (EluNIR) in Coronary Stenosis Trial
Role: lead
IonMAN Trial- First in Human Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System
Role: lead
MedJ-01 Ridaforolimus Eluting Coronary Stent System Trial (JNIR)
Role: lead
Study of BioNIR Drug Eluting Stent System in Coronary Stenosis
Role: lead
NIRTRAKS Post-Market Study (NIRTRAKS)
Role: lead
ChampioNIR® SFA Stent EFS Study
Role: lead
X-MAS Biliary Study With Covered Biliary Stent
Role: lead
BIONICS - Pharmacokinetics (PK) Trial
Role: lead
EluNIR Ridaforolimus Eluting Coronary Stent System in Patients at High Bleeding Risk (HBR)- EluNIR HBR Study
Role: lead
Angiography Study of BioNIR Drug Eluting Stent System (NIREUS)
Role: lead
BIONICS 38 mm Trial EluNIR Ridaforolimus Eluting Coronary Stent System (EluNIR) In Coronary Stenosis Trial
Role: lead
BIONICS Israel Trial
Role: lead
PIONIR Study (Presillion™ and Presillion™ Plus Stent Systems)
Role: lead
Dedicated Sheath Feasibility Study
Role: collaborator
All 16 trials loaded